<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:aavptbiennial-ojs-tamu.tdl.org:article/198</identifier>
				<datestamp>2024-10-30T19:15:56Z</datestamp>
				<setSpec>aavptbiennial:S3</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">The Acute Therapy of Supraventricular Tachycardia with Verapamil</dc:title>
	<dc:creator xml:lang="en">Kittleson, Mark D.</dc:creator>
	<dc:creator xml:lang="en">Keene, Bruce W.</dc:creator>
	<dc:creator xml:lang="en">Woodfield, Jerry A.</dc:creator>
	<dc:subject xml:lang="en">verapamil</dc:subject>
	<dc:subject xml:lang="en">supraventricular tachycardia</dc:subject>
	<dc:subject xml:lang="en">digoxin</dc:subject>
	<dc:subject xml:lang="en">propranolol</dc:subject>
	<dc:subject xml:lang="en">calcium movement</dc:subject>
	<dc:description xml:lang="en">We have used intravenous verapamil to treat spontaneous occurrences of supraventricular tachycardia in 9 dogs. The dose has ranged from 0.05 mg/kg to 0.15 mg/kg administered in boluses of 0.05 mg/kg given over 30-60 seconds. Verapamil was successful at terminating the arrhythmia in 8 of the 9 cases. Only 1 dog went on to receive oral verapamil which controlled the arrhythmia at a dose of approximately 1 mg/kg. The other dogs were managed chronically with digoxin and/or propranolol. The one dog that did not respond became hypotensive after receiving a total dose of 0.15 mg/kg but recovered. An ECG of a dog with supraventricular tachycardia before and after the administration of 0.1 mg/kg verapamil is presented in figure 1.
In summary, verapamil is a drug that decreases the slow inward movement of calcium in various cardiac cells. This action makes it useful for prolonging conduction velocity and the refractory period in the AV node to "break" reentrant supraventricular tachycardia. We have found the drug useful for this effect in dogs with supraventricular tachycardia.</dc:description>
	<dc:publisher xml:lang="en">AAVPT Biennial Symposia</dc:publisher>
	<dc:date>1986-06-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://aavptbiennial-ojs-tamu.tdl.org/aavptbiennial/article/view/198</dc:identifier>
	<dc:source xml:lang="en">AAVPT Biennial Symposia; Fifth Biennial Symposium; 97-107</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://aavptbiennial-ojs-tamu.tdl.org/aavptbiennial/article/view/198/188</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 1986 American Academy of Veterinary Pharmacology and Therapeutics</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
